@article{a6b14a5a5b8243d39f1b5ebb8e2ac460,
title = "Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter",
keywords = "aficamten, cardiac myosin inhibitors, hypertrophic cardiomyopathy, mavacamten, myectomy",
author = "Ahmad Masri and Iacopo Olivotto",
note = "Funding Information: Masri has received research grants from Pfizer, Ionis, Akcea, Ultromics and the Wheeler Foundation, fees (honoraria or consulting) from Eidos, Pfizer, Ionis, Alnylam, Cytokinetics, Bristol Meier Squibb, Tenaya, and Attralus, and served or currently serving as PI on EXPLORER-HCM, PIONEER-OLE, MAVA-LTE, VALOR-HCM, REDWOOD-HCM, REDWOOD-OLE, and SEQUOIA-HCM trials. Olivotto has received grants from Bristol Meier Squibb, Cytokinetics, Amicus, Genzyme, Shire, Bayer, Boston Scientific, Menarini International, and fees (honoraria or consulting) from Bristol Meier Squibb, Cytokinetics, Amicus, Genzyme, Shire, Boston Scientific, and served or currently serving as PI on EXPLORER-HCM, MAVA-LTE, REDWOOD-HCM, REDWOOD-OLE, and SEQUOIA-HCM trial.",
year = "2022",
month = may,
day = "3",
doi = "10.1161/JAHA.121.024656",
language = "English (US)",
volume = "11",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "9",
}